What is Valneva?
Valneva SE operates as a specialty biotechnology firm dedicated to the research, development, and commercialization of prophylactic vaccines. The company addresses critical public health challenges by targeting infectious diseases that currently lack effective preventive options. By integrating advanced manufacturing capabilities with a robust R&D framework, Valneva has established itself as a vital contributor to global health security. Its market position is bolstered by a diversified portfolio that spans both proprietary vaccine candidates and strategic collaborations with global pharmaceutical leaders, allowing the firm to leverage shared expertise and infrastructure to accelerate time-to-market for its innovative medical solutions.
How much funding has Valneva raised?
Valneva has raised a total of $749.8M across 5 funding rounds:
Debt
$27.6M
Debt
$100M
Grant
$27.2M
Corporate Investment
$95M
Debt
$500M
Debt (2016): $27.6M with participation from European Investment Bank
Debt (2020): $100M led by Orbimed and Deerfield Management
Grant (2022): $27.2M, investors not publicly disclosed
Corporate Investment (2022): $95M featuring Pfizer
Debt (2025): $500M, investors not publicly disclosed
Key Investors in Valneva
Orbimed
Orbimed is a leading healthcare-dedicated investment firm that provides capital to companies across the biopharmaceutical and medical device sectors.
Deerfield Management
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem with flexible funding models.
European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution.
What's next for Valneva?
With the recent influx of capital, Valneva is well-positioned to scale its manufacturing capacity and accelerate the clinical development of its late-stage vaccine candidates. The strategic focus will likely shift toward optimizing commercialization pathways and expanding its footprint in key international markets. As the company navigates the complexities of the global vaccine landscape, the continued support from institutional investors and corporate partners will be instrumental in maintaining its competitive edge. Future growth will be driven by the successful execution of its pipeline, potential regulatory approvals, and the ongoing refinement of its proprietary vaccine technology platforms, ensuring that Valneva remains at the forefront of infectious disease prevention.
See full Valneva company page
